Resumen

ZUNIGA, Andrés et al. Oral antidiabetic drugs and their interaction with disease-modifying drugs. Rev. virtual Soc. Parag. Med. Int. [online]. 2020, vol.7, n.1, pp.107-111. ISSN 2312-3893.  https://doi.org/10.18004/rvspmi/2312-3893/2020.07.01.107-111.

Oral antidiabetics drugs (OADs) in patients with diabetes mellitus 2 and with rheumatic comorbidities have not demonstrated relevant interaction with disease-modifying drugs (DMARDs). It should be remembered that taking several medications increases the risk of interactions or adverse effects especially if these have their metabolism in the same organ. The objective is to make known what interactions exist between OADs and DMARDs, by searching for review articles, pharmacological guides and studies. The most outstanding result was the finding of a study that covers the use of a DPP-4 (dipeptidyl peptidase-4 inhibitor), specifically sitagliptin as a protective effect against the toxicity produced by methotrexate. In patients with rheumatic diseases who also suffer from diabetes mellitus 2, the use of hydroxychloroquine has been shown to reduce lipid levels, but not specifically as a drug interaction with any OADs, it is an innate property of hydroxychloroquine. Evidence was found that there is a correlation of hypoglycemia in patients taking secretagogue drugs and sulfasalazine.

Palabras clave : hypoglycemic agents; drug interactions; type 2 diabetes mellitus; hydroxychloroquine; methotrexate.

        · resumen en Español     · texto en Español     · Español ( pdf )